Theratechnologies Buchwert je Aktie
Was ist das Buchwert je Aktie von Theratechnologies?
Buchwert je Aktie von Theratechnologies Inc. ist 0.16
Was ist die Definition von Buchwert je Aktie?
Der Buchwert pro Aktie ist das Vermögen eines Unternehmens abzüglich der Verbindlichkeiten geteilt durch die Anzahl der ausstehenden Aktien.
The book value of a company is the value of its assets according to its balance sheet account balance. For assets, the value is based on the original cost of the asset less any depreciation, amortization or impairment costs made against the asset. Traditionally, a company's book value is its total assets minus intangible assets and liabilities. However, in practice, depending on the source of the calculation, book value may variably include goodwill, intangible assets, or both. The value inherent in its workforce, part of the intellectual capital of a company, is always ignored. The book value of a company may be also referred as with the term net asset value.
The book value per share is the the balance sheet equity value divided by the number of shares outstanding at the date of the balance sheet. Book value per share can be used to generate a measure of comprehensive earnings, when the opening and closing values are reconciled. The sale of shares/units by a business increases the total book value. Book value per share will increase if the additional shares are issued at a price higher than the pre-existing book value per share. The purchase of its own shares by a business will decrease total book value. Book value per share will decrease if more is paid for them than was received when originally issued. Dividends paid out will decrease book value per share value.
Buchwert je Aktie von Unternehmen in Health Care Sektor auf NASDAQ im Vergleich zu Theratechnologies
Was macht Theratechnologies?
theratechnologies inc., a biopharmaceutical company, markets prescription products in the united states, europe, and canada. it offers egrifta and egrifta sv, for the reduction of excess abdominal fat in human immunodeficiency virus (hiv)-infected patients with lipodystrophy; and trogarzo, an injection refers to ibalizumab for the treatment of multidrug resistant hiv-1 infected patients. the company's pipeline products include f8 formulation that could be used for the treatment of hiv-associated lipodystrophy; th-1902 for the treatment of triple negative breast cancer; and th-1904 for the treatment of ovarian cancer. the company was founded in 1993 and is headquartered in montreal, canada.
Unternehmen mit buchwert je aktie ähnlich Theratechnologies
- China City Infrastructure hat Buchwert je Aktie von 0.16
- Healthcare Merger hat Buchwert je Aktie von 0.16
- FinServ Acquisition Corp hat Buchwert je Aktie von 0.16
- Sezzle hat Buchwert je Aktie von 0.16
- ZincX Resources hat Buchwert je Aktie von 0.16
- Dingdong (Cayman) Ltd hat Buchwert je Aktie von 0.16
- Theratechnologies hat Buchwert je Aktie von 0.16
- Vivos Therapeutics hat Buchwert je Aktie von 0.16
- Tritent International hat Buchwert je Aktie von 0.16
- Garibaldi Resources hat Buchwert je Aktie von 0.16
- Fujian hat Buchwert je Aktie von 0.16
- Nova Minerals hat Buchwert je Aktie von 0.16
- Kwan Yong hat Buchwert je Aktie von 0.16